
There are significant associations between the increased numbers of telangiectases in patients with scleroderma and the presence of pulmonary arterial hypertension (PAH). Cutaneous telangiectases may be a manifestation of the vasculopathy of scleroderma that could serve as a clinical biomarker for pulmonary vascular disease.






